Bluebird Bio (BLUE) said Wednesday its board reaffirmed its support for its planned acquisition by Carlyle (CG) and SK Capital as Ayrmid has not sent a binding or fully financed offer after three weeks of engagement, including a timeline extension.
Bluebird said Ayrmid's proposal remained "highly conditional" even after it engaged with Ayrmid on two occasions.
The company said it has recommended that all stockholders tender by May 2 into the current agreement with Carlyle and SK Capital.
Under the deal announced in February, Bluebird agreed to be acquired and taken private by funds managed by Carlyle and SK Capital for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.
Shares of Bluebird were down more than 6% in recent trading Wednesday.
Price: 4.19, Change: -0.28, Percent Change: -6.26
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。